Immunomodulating Drugs in Myelodysplastic Syndromes
نویسندگان
چکیده
منابع مشابه
Immunomodulating Drugs
Immunopharmacology is the study of the use of pharmacological agents as modulators of immune responses. The principal applications are in the use of immunosuppressive agents (i.e., compounds that suppress undesirable immune responses) and immunostimulating agents (i.e., drugs, microorganisms, or biological products that enhance or augment immune responses). Three major indications for immunothe...
متن کاملMyelodysplastic Syndromes Myelodysplastic syndromes: recent advances
Etiology of myelodysplastic syndromes The models for the development of sporadic MDS suggest the role of cumulative environmental exposures in genetically predisposed individuals. There is increasing evidence for a complex genetic predisposition to MDS involving naturally occurring DNA polymorphisms in genes that mediate DNA repair and metabolize environmental carcinogens.3 Large epidemiologic ...
متن کاملMyelodysplastic syndromes.
The myelodysplastic syndromes are a heterogeneous group of hematopoietic stem cell disorders characterized by dysplastic and ineffective hematopoiesis and a varying risk of transformation to acute leukemia. Although the natural history of these syndromes is variable, several factors appear to be of prognostic importance, including the French-American-British classification, the karyotype, in vi...
متن کاملMyelodysplastic syndromes.
These two issues of the Seminars in Hematology will provide the physician the necessary knowledge to help make sense of this somewhat confusing array of diseases. The subdivisions of MDS reflect the precision of our techniques of dissection, with morphological and histochemical analyses forming the foundation to identify and subdivide MDS. Although steady refinement has occurred over the last h...
متن کاملMyelodysplastic syndromes.
There has been a remarkable explosion of knowledge into the molecular defects that underlie the acute and chronic leukemias, leading to the introduction of targeted therapies that can block key cellular events essential for the viability of the leukemic cell. Our understanding of the pathogenesis of the myelodysplastic syndromes (MDSs) has lagged behind, at least in part, because they represent...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Hematology
سال: 2011
ISSN: 1520-4391,1520-4383
DOI: 10.1182/asheducation-2011.1.556